An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks)

Outcome Description:

Results are presented as the number of subjects with at least one treatment-emergent adverse event during this study.

Outcome Time Frame:

During this study (maximum 122 weeks)

Safety Issue:

No

Principal Investigator

UCB Clinical Trial Call Center

Investigator Role:

Study Director

Investigator Affiliation:

+1 877 822 9493 (UCB)

Authority:

United States: Food and Drug Administration

Study ID:

C87065

NCT ID:

NCT00356408

Start Date:

January 2007

Completion Date:

February 2010

Related Keywords:

• Crohn's Disease
• CDP870
• certolizumab pegol
• Crohn's Disease
• Crohn Disease